SENTARA COMMUNITY PLAN
(MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-844-305-2331**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization can be delayed**.

Somatostatin Analog Drugs (MEDICAL)

Drug Requested: Check box below that applies.

PREFERRED	
❑ **lanreotide acetate extended release SQ injection 120 mg/0.5 mL (J1932)**	❑ **octreotide injection** (generic Sandostatin®) **(J2354)**
❑ **Sandostatin®** (octreotide) **injection (J2353)**	❑ **Signifor LAR®** (pasireotide) **SQ injection (J2502)**
NON-PREFERRED	
❑ **Somatuline® Depot** (lanreotide) **injection 60 mg, 90 mg, 120 mg (J1930)**	

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight: _____ **Date:** _____

❑ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

****Somatostatin analogs used for cancer treatment is outlined in NCCN guidelines for Neuroendocrine Tumors****

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

❑ **Diagnosis: Acromegaly (octreotide, Sandostatin*, Signifor LAR, Somatuline*)**
If brand Sandostatin or Somatuline is requested, provider must submit documentation to confirm treatment failure, contraindication or intolerance to the generic product

Initial Authorization: 12 months

- ❑ Member is 18 years of age or older

AND

- ❑ Provider is an endocrinologist or neurosurgeon

AND

- ❑ Member has undergone pituitary surgery and/or irradiation is contraindicated **(chart notes must be submitted to document diagnosis and surgical history or contraindication to surgery)**

AND

- ❑ Diagnosis has been confirmed by elevated IGF levels as well as inadequate suppression of growth hormone (GH) levels **(labs must be submitted for documentation)**

AND

- ❑ **For Signifor LAR or Somatuline Depot 60 mg, 90 mg:**
  - ❑ Medication will not be used in combination with other short-acting somatostatin analogs
  - ❑ Member must have tried and failed generic octreotide

OR

- ❑ **For Somatuline Depot 120 mg:**
  - ❑ Medication will not be used in combination with other short-acting somatostatin analogs
  - ❑ Member must have tried and failed generic lanreotide 120 mg

❑ **Diagnosis: Acromegaly (octreotide, Sandostatin*, Signifor LAR, Somatuline*)**
If brand Sandostatin or Somatuline is requested, provider must submit documentation to confirm treatment failure, contraindication or intolerance to the generic product

Reauthorization: 12 months

- ❑ No toxicity has been observed while taking the requested medication

AND

(Continued on next page)

- ❑ Response is demonstrated by **BOTH** of the following **(Chart notes must be submitted for documentation)**:
  - ❑ Reduction of GH levels from pre-treatment baseline
  - ❑ Normalization of IGF level

AND

- ❑ **For Signifor LAR and Somatuline Depot, all strengths:** Member has not had to use short-acting somatostatin therapy during treatment

❑ **Diagnosis: Carcinoid Syndrome (octreotide, Sandostatin*, Somatuline*)**
If brand Sandostatin or Somatuline is requested, provider must submit documentation to confirm treatment failure, contraindication or intolerance to the generic product

Authorization Criteria: 6 months

- ❑ Member has **ONE** of the following **(Chart notes must be submitted for documentation)**:
  - ❑ Severe diarrhea/flushing episodes (carcinoid syndrome) related to hormone hypersecretion in neuroendocrine tumors
  - ❑ Prophylactic administration prior to induction of anesthesia in an individual with a functional carcinoid tumor
  - ❑ Prophylactic administration perioperatively to a surgical procedure in an individual with a functional carcinoid tumor

AND

- ❑ **For Somatuline Depot, all strengths:** Member must have tried and failed generic lanreotide

❑ **Diagnosis: Diarrhea associated with Vasoactive Intestinal Peptide tumors (VIPomas) (octreotide, Sandostatin*, Signifor LAR)**
If brand Sandostatin is requested, provider must submit documentation to confirm treatment failure, contraindication or intolerance to the generic product

Authorization Criteria: 6 months

- ❑ Member has profuse watery diarrhea associated with VIPomas **(Chart notes must be submitted for documentation)**

❑ **Diagnosis: Cushing's Disease (Signifor LAR)**

Initial Authorization: 3 months

- ❑ Member is 18 years of age or older

AND

(Continued on next page)

- ❑ Provider is an endocrinologist or neurosurgeon

AND

- ❑ Member has a diagnosis of Cushing's disease and pituitary surgery is not an option or has not been curative (**chart notes must be submitted to document diagnosis and surgical history or contraindication to surgery)**

AND

- ❑ Member's baseline 24-hour urinary free cortisol level is greater than 1.5 times the upper limit of normal **(labs must be submitted for documentation)**

AND

- ❑ Current baseline labs documenting **ALL** of the following must be attached: liver function tests, fasting plasma glucose, hemoglobin A1c, thyroid function, baseline ECG, and gallbladder ultrasound

❑ Diagnosis: Cushing's Disease (Signifor LAR)

Reauthorization: 12 months

- ❑ Member's current 24-hour urinary free cortisol level is below the upper limit of normal mean **(labs must be submitted for documentation)**

AND

- ❑ Current labs documenting member's liver function, fasting plasma glucose and hemoglobin A1c must be submitted with request

AND

- ❑ Improvements in blood pressure, triglycerides, low-density lipoprotein cholesterol, weight and health related quality of life have been maintained while on Signifor therapy **(Chart notes must be submitted for documentation)**

❑ Diagnosis: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) (Somatuline*)

If brand Somatuline is requested, provider must submit documentation to confirm treatment failure, contraindication or intolerance to the generic product

Initial Authorization: 12 months

- ❑ Diagnosis must be confirmed through chart notes and medical claims

(Continued on next page)

❑ **Diagnosis: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) (Somatuline*)** ***If brand Somatuline is requested, provider must submit documentation to confirm treatment failure, contraindication or intolerance to the generic product***
Reauthorization: 12 months

❑ No toxicity has been observed while taking Somatuline

❑ **Diagnosis: Other**
Please submit documentation showing medical necessity

Medication being provided by a Specialty Pharmacy - PropriumRx

❑ **Location/site of drug administration:** _____

NPI or DEA # of administering location: _____

OR

❑ **Specialty Pharmacy - PropriumRx**

For urgent reviews: Practitioner should call Sentara Health Plans Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health Plan's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

***Approved by Pharmacy & Therapeutic Committee:** 11/19/2020
REVISED/UPDATED/REFORMATTED: ~~4/1/2021; 6/14/2021; 10/11/2021~~**; ~~4/7/2022;~~** ~~4/26/2022; 6/15/2022;~~ ~~12/7/2022;~~ **2/29/2024**